Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Ocrelizumab in RRMS (OVERLORD-MS)
NCT04578639Phase 3Active, not recruiting
- Sponsor
- Haukeland University Hospital
- Start
- Nov 2020
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of rituximab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Haukeland University Hospital. Primary endpoint: Proportion of patients with no new or enlarging T2-weighted brain MRI lesions. Started Nov 2020; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04578639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578639.